Robert Campbell Tait

List of Publications by Year
in descending order

160	8,656	57681	51423
papers	citations	46 h-index	90 g-index

163	163	163	7416
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. Blood Advances, 2022, 6, 902-908.	2.5	15
2	Correction of international normalised ratio in major bleeding related to vitamin K antagonists is associated with better survival: A UK study. Thrombosis Research, 2021, 197, 153-159.	0.8	1
3	Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. Heart, 2021, 107, 299-312.	1.2	6
4	New Inhibitors in the Ageing Population: A retrospective, observational, cohort study of new inhibitors in older people with haemophilia. Thrombosis and Haemostasis, 2021, , .	1.8	0
5	Clinical and radiological characteristics of acute pulmonary embolus in relation to 28-day and 6-month mortality. PLoS ONE, 2021, 16, e0258843.	1.1	2
6	TCT CONNECT-16 Implications of Impaired Coronary Flow on the Effects of Intracoronary Alteplase During Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2020, 76, B7-B8.	1.2	0
7	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood, 2020, 136, 1956-1967.	0.6	34
8	A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients. Thrombosis and Haemostasis, 2020, 120, 747-757.	1.8	8
9	Macroscopic hematuria as a risk factor for hypertension in ageing people with hemophilia and a family history of hypertension. Medicine (United States), 2020, 99, e19339.	0.4	6
10	Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time. Journal of the American College of Cardiology, 2020, 75, 1406-1421.	1.2	16
11	A new pedigree with thrombomodulinâ€associated coagulopathy in which delayed fibrinolysis is partially attenuated by coâ€inherited TAFI deficiency. Journal of Thrombosis and Haemostasis, 2020, 18, 2209-2214.	1.9	16
12	Hematuria in aging men with hemophilia: Association with factor prophylaxis. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 309-317.	1.0	7
13	Effects of Intracoronary Alteplase on Microvascular Function in Acute Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e014066.	1.6	11
14	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-86.	0.9	0
15	History of the West of Scotland Haemophilia Centre, Glasgow, 1950â€“2019. Journal of the Royal College of Physicians of Edinburgh, The, 2020, 50, 330-338.	0.2	0
16	Haematological management of major bleeding associated with direct oral anticoagulants â€“ UK experience. British Journal of Haematology, 2019, 185, 514-522.	1.2	15
17	Performance of the LumiraDx Platform INR Test in an Anticoagulation Clinic Point-of-Care Setting Compared With an Established Laboratory Reference Method. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961989042.	0.7	2
18	Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2019, 321, 56.	3.8	88

#	Article	IF	Citations
19	A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study). Haematologica, 2018, 103, 738-745.	1.7	30
20	The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment. Medicine (United States), 2018, 97, e12551.	0.4	12
21	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. American Journal of Human Genetics, 2018, 103, 144-153.	2.6	36
22	Individual and monitoring centre influences upon anticoagulation control of <scp>AF</scp> patients on warfarin: A longitudinal multiâ€centre <scp>UK</scp>â€based study. European Journal of Haematology, 2018, 101, 486-495.	1.1	0
23	British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism. BMJ Open Respiratory Research, 2018, 5, e000281.	1.2	16
24	British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE). Thorax, 2018, 73, ii1-ii29.	2.7	58
25	Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia. Blood, 2017, 129, 520-524.	0.6	42
26	A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins. Clinical Pharmacokinetics, 2017, 56, 1555-1566.	1.6	9
27	Spontaneous sublingual haematoma in acquired haemophilia: case report. British Journal of Oral and Maxillofacial Surgery, 2017, 55, e17-e18.	0.4	5
28	Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation, 2017, 136, 2022-2033.	1.6	111
29	Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation. Thrombosis and Haemostasis, 2016, 116, 578-580.	1.8	10
30	<scp>FVIII</scp> inhibitor development according to concentrate: data from the <scp>EUHASS</scp> registry excluding overlap with other studies. Haemophilia, 2016, 22, e36-8.	1.0	11
31	Hypertension, haematuria and renal functioning in haemophilia â€“ a crossâ€sectional study in Europe. Haemophilia, 2016, 22, 248-255.	1.0	39
32	An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events. Leukemia and Lymphoma, 2016, 57, 2568-2574.	0.6	21
33	How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population. Haemophilia, 2016, 22, e406-16.	1.0	9
34	Periâ€operative management of anticoagulation and antiplatelet therapy. British Journal of Haematology, 2016, 175, 602-613.	1.2	159
35	Influence of Genotype on Warfarin Maintenance Dose Predictions Produced Using a Bayesian Dose Individualization Tool. Therapeutic Drug Monitoring, 2016, 38, 677-683.	1.0	10
36	Guideline on aspects of cancerâ€related venous thrombosis. British Journal of Haematology, 2015, 170, 640-648.	1.2	139

#	Article	IF	Citations
37	Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. Journal of Thrombosis and Haemostasis, 2015, 13, 1815-1822.	1.9	27
38	Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. Journal of Thrombosis and Haemostasis, 2015, 13, 775-781.	1.9	57
39	Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke. Stroke, 2015, 46, 3543-3546.	1.0	37
40	Renal Status and Hematuria in Older Patients with Hemophilia. Blood, 2015, 126, 2290-2290.	0.6	1
41	Hemostasis and Anticoagulants. , 2014, , 479-496.		3
42	The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emergency Medicine Journal, 2014, 31, 163-168.	0.4	64
43	Oral anticoagulant agentâ€associated bleeding events reporting system (<scp>ORANGE</scp>) study. British Journal of Haematology, 2014, 167, 274-276.	1.2	1
44	Evaluation of the effects of single-nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses: comment. Journal of Thrombosis and Haemostasis, 2014, 12, 1196-1197.	1.9	0
45	Obstructive Uropathy and Vesicovaginal Fistula Secondary to a Retained Sex Toy in the Vagina. Journal of Sexual Medicine, 2014, 11, 2595-2600.	0.3	15
46	The diagnosis and management of von <scp>W</scp>illebrand disease: a <scp>U</scp>nited <scp>K</scp>ingdom <scp>H</scp>aemophilia <scp>C</scp>entre <scp>D</scp>octors <scp>O</scp>rganization guideline approved by the <scp>B</scp>ritish <scp>C</scp>ommittee for <scp>S</scp>tandards in <scp>H</scp>aematology. British Journal of Haematology, 2014, 167, 453-465.	1.2	297
47	Perioperative and peripartum prevention of venous thromboembolism in patients with hereditary antithrombin deficiency using recombinant antithrombin therapy. Blood Coagulation and Fibrinolysis, 2014, 25, 444-450.	0.5	18
48	Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences. Journal of Clinical Epidemiology, 2013, 66, 415-425.	2.4	11
49	Guideline on the management of bleeding in patients on antithrombotic agents. British Journal of Haematology, 2013, 160, 35-46.	1.2	197
50	Correlating prothrombin time with plasma rivaroxaban level. British Journal of Haematology, 2013, 163, 685-687.	1.2	11
51	Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia - an assessment by the ADVANCE Working Group. Haemophilia, 2013, 19, 833-840.	1.0	52
52	Hepatitis C infection and outcomes in the Scottish haemophilia population. Haemophilia, 2013, 19, 870-875.	1.0	8
53	Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thrombosis and Haemostasis, 2013, 109, 16-23.	1.8	62
54	Increased prevalence of hypertension in haemophilia patients. Thrombosis and Haemostasis, 2012, 108, 750-755.	1.8	66

#	Article	IF	Citations
55	History of nonâ€fatal cardiovascular disease in a cohort of <scp>D</scp>utch and <scp>B</scp>ritish patients with haemophilia. European Journal of Haematology, 2012, 89, 336-339.	1.1	32
56	Guidelines on the investigation and management of venous thrombosis at unusual sites. British Journal of Haematology, 2012, 159, 28-38.	1.2	119
57	C0353 United Kingdom consensus based practical guide for the management of haemorrhage in patients receiving dabigatran. Thrombosis Research, 2012, 130, S114-S115.	0.8	1
58	Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). Journal of Thrombosis and Haemostasis, 2012, 10, 1019-1025.	1.9	353
59	Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology, 2012, 157, 47-58.	1.2	492
60	Polymorphisms in <scp>VKORC</scp>1 have more impact than <scp>CYP2C9</scp> polymorphisms on early warfarin <scp>I</scp>nternational <scp>N</scp>ormalized <scp>R</scp>atio control and bleeding rates. British Journal of Haematology, 2012, 158, 256-261.	1.2	41
61	Guidelines on oral anticoagulation with warfarin â€“ fourth edition. British Journal of Haematology, 2011, 154, 311-324.	1.2	482
62	F8 and F9 mutations fail to coâ€segregate in a family with coâ€incident haemophilia A and B. Haemophilia, 2011, 17, e230-4.	1.0	11
63	A novel, biodegradable and reversible polyelectrolyte platform for topical-colonic delivery of pentosan polysulphate. International Journal of Pharmaceutics, 2011, 404, 124-132.	2.6	6
64	Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ: British Medical Journal, 2011, 342, d813-d813.	2.4	218
65	Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score. Blood, 2011, 118, 544-544.	0.6	3
66	Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patientâ€level metaâ€analysis. Journal of Thrombosis and Haemostasis, 2010, 8, 2436-2442.	1.9	181
67	Molecular characterization of 11 novel mutations in patients with heterozygous and homozygous FV deficiency. Haemophilia, 2010, 16, 937-942.	1.0	14
68	Clinical guidelines for testing for heritable thrombophilia. British Journal of Haematology, 2010, 149, 209-220.	1.2	434
69	Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of<scp>d</scp>-Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2010, 153, 523.	2.0	149
70	Antithrombin-Î± for the prophylaxis of venous thrombosis in congenital antithrombin deficiency. Expert Review of Hematology, 2009, 2, 499-507.	1.0	3
71	Changing patterns of bleeding in patients with severe haemophilia A. Haemophilia, 2009, 15, 1210-1214.	1.0	109
72	Authorsâ€™ reply: Vitamin B12 deficiency following restorative proctocolectomy (Colorectal Dis. 2007) Tj ETQq0 0 0 rgBT /Overlock 10	0.7	0

#	Article	IF	Citations
73	Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia, 2008, 14, 671-684.	1.0	206
74	Systematic Review: <scp>d</scp>-Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2008, 149, 481.	2.0	234
75	Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. Thrombosis and Haemostasis, 2008, 99, 616-622.	1.8	37
76	Antithrombin Alfa in Hereditary Antithrombin Deficient Patients at High Risk for Thromboembolic Complications. Blood, 2008, 112, 986-986.	0.6	1
77	Hereditary and Acquired Antithrombin Deficiency. Drugs, 2007, 67, 1429-1440.	4.9	144
78	Vitamin B12 deficiency following restorative proctocolectomy. Colorectal Disease, 2007, 9, 562-566.	0.7	38
79	Reversal of asymptomatic over-anticoagulation with oral vitamin K. British Journal of Haematology, 2006, 135, 591-592.	1.2	1
80	Are Atrial Fibrillation Guidelines Altering Management? A Community Based Study. Scottish Medical Journal, 2005, 50, 166-169.	0.7	8
81	Use of Recombinant Activated Factor VII for Bleeding in Pancreatitis. Pancreas, 2005, 30, 279-284.	0.5	14
82	The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype. British Journal of Haematology, 2005, 128, 830-836.	1.2	28
83	Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. American Journal of Clinical Nutrition, 2005, 82, 1320-1326.	2.2	129
84	Characterization of plasminogen variants in healthy subjects and plasminogen mutants in patients with inherited plasminogen deficiency by isoelectric focusing gel electrophoresis. Thrombosis and Haemostasis, 2004, 92, 352-357.	1.8	11
85	Restarting Oral Anticoagulation After Intracranial Hemorrhage. Stroke, 2004, 35, e5-6; author reply e5-6.	1.0	7
86	The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population. British Journal of Haematology, 2004, 125, 647-654.	1.2	51
87	Immediate haemostasis with recombinant factor VIIa for haemorrhage following Hickman line insertion in acute myeloid leukaemia. International Journal of Laboratory Hematology, 2004, 26, 229-231.	0.2	11
88	Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. Journal of Thrombosis and Haemostasis, 2004, 2, 1873-1878.	1.9	102
89	A two-phase audit of fresh frozen plasma: a regional approach. Transfusion Medicine, 2004, 14, 75-76.	0.5	10
90	'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sanguinis, 2004, 86, 120-124.	0.7	122

#	Article	IF	Citations
91	Identification of Ten Novel Mutations Associated with Inherited Coagulation Factor V Deficiency.. Blood, 2004, 104, 1030-1030.	0.6	0
92	Anticoagulation with warfarin downregulates inflammation. Journal of Thrombosis and Haemostasis, 2003, 1, 1838-1839.	1.9	22
93	Plasma protein Z deficiency is common in women with antiphospholipid antibodies. British Journal of Haematology, 2003, 120, 913-914.	1.2	29
94	Successful elimination of factor VIII inhibitor using Cyclosporin A. British Journal of Haematology, 2003, 122, 1024-1025.	1.2	3
95	Interaction between hormone replacement therapy preparations and oral anticoagulant therapy. BJOG: an International Journal of Obstetrics and Gynaecology, 2003, 110, 777-779.	1.1	17
96	A K19E missense mutation in the plasminogen gene is a common cause of familial hypoplasminogenaemia. Blood Coagulation and Fibrinolysis, 2003, 14, 411-416.	0.5	17
97	Coeliac disease presenting as variceal haemorrhage. Gut, 2003, 52, 758-758.	6.1	8
98	Interaction between hormone replacement therapy preparations and oral anticoagulant therapy. BJOG: an International Journal of Obstetrics and Gynaecology, 2003, 110, 777-9.	1.1	1
99	Treatment of acquired haemophilia. Internal Medicine Journal, 2002, 32, 625-626.	0.5	2
100	P24. Value of a negative D-dimer result in the evaluation of suspected acute pulmonary embolism: The Glasgow Royal Infirmary experience. Nuclear Medicine Communications, 2002, 23, 412-413.	0.5	0
101	Injecting drug use is a risk factor for deep vein thrombosis in women in Glasgow. British Journal of Haematology, 2001, 112, 641-643.	1.2	55
102	A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. British Journal of Haematology, 2001, 113, 636-641.	1.2	195
103	Platelet and cardiac function in Darier's disease. Clinical and Experimental Dermatology, 2001, 26, 696-699.	0.6	36
104	Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review. Haemophilia, 2001, 7, 160-163.	1.0	38
105	Oral Anticoagulation and Hemorrhagic Complications in an Elderly Population With Atrial Fibrillation. Archives of Internal Medicine, 2001, 161, 2125.	4.3	99
106	Anticoagulation in patients with thromboembolic disease. Thorax, 2001, 56 Suppl 2, ii30-7.	2.7	0
107	Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism. British Journal of Haematology, 2000, 108, 272-274.	1.2	82
108	A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. British Journal of Haematology, 2000, 109, 537-539.	1.2	50

#	Article	IF	Citations
109	Prothrombin 20210 GA, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 565-569.	1.1	74
110	Hysterectomy techniques and their effect on the blood markers of thrombogenicity. Gynaecological Endoscopy, 2000, 9, 379-383.	0.3	2
111	Low-molecular-weight heparin as optimal solution to therapeutic heparinization. American Heart Journal, 2000, 139, 558-560.	1.2	1
112	Stenotrophomonas Maltophilia: An Increasing Problem in Patients with Acute Leukaemia. Leukemia and Lymphoma, 1999, 35, 207-211.	0.6	20
113	Acquired activated protein C resistance in pregnancy is not due to elevated plasma caeruloplasmin levels. British Journal of Haematology, 1999, 105, 1149-1150.	1.2	1
114	Activated protein C resistance in normal pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 1998, 105, 1129-1130.	1.1	4
115	Activated protein C resistance in normal pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 1998, 105, 473-474.	1.1	2
116	A warfarin induction regimen for outâ€patient anticoagulation in patients with atrial fibrillation. British Journal of Haematology, 1998, 101, 450-454.	1.2	55
117	Restarting anticoagulation in prosthetic heart valve patients after intracranial haemorrhage: a 2-year follow-up. British Journal of Haematology, 1998, 103, 1064-1066.	1.2	77
118	ANTITHROMBIN CONCENTRATE ALONE MAY NOT PREVENT VENOUS THROMBOEMBOLISM FOLLOWING NEUROSURGERY. British Journal of Haematology, 1998, 103, 583-584.	1.2	0
119	Management of oral anticoagulant-induced intracranial haemorrhage. Blood Reviews, 1998, 12, 35-44.	2.8	101
120	Blood Ordering Practices in Elective and Emergency Surgical Procedures. Scottish Medical Journal, 1998, 43, 154-155.	0.7	0
121	Superficial Vein Thrombosis: Incidence in Association with Pregnancy and Prevalence of Thrombophilic Defects. Thrombosis and Haemostasis, 1998, 79, 741-742.	1.8	34
122	Antithrombin Cambridge II (Ala384Ser): Clinical, Functional and Haplotype Analysis of 18 Families. Thrombosis and Haemostasis, 1998, 79, 249-253.	1.8	21
123	Antithrombin cambridge II (Ala384Ser): clinical, functional and haplotype analysis of 18 families. Thrombosis and Haemostasis, 1998, 79, 249-53.	1.8	5
124	Superficial vein thrombosis: incidence in association with pregnancy and prevalence of thrombophilic defects. Thrombosis and Haemostasis, 1998, 79, 741-2.	1.8	6
125	Asymptomatic coinheritance of heterozygous plasminogen deficiency and the factor VLeiden mutation. Blood Coagulation and Fibrinolysis, 1997, 8, 195-199.	0.5	11
126	Superficial vein thrombosis. Blood Coagulation and Fibrinolysis, 1997, 8, 462.	0.5	0

#	Article	IF	Citations
127	The role of hepatitis C virus in the aetiology of non-Hodgkins lymphoma-A regional association?. Leukemia and Lymphoma, 1997, 26, 127-130.	0.6	88
128	Risk Factors for Pregnancy Associated Venous Thromboembolism. Thrombosis and Haemostasis, 1997, 78, 1183-1188.	1.8	358
129	Risk factors for pregnancy associated venous thromboembolism. Thrombosis and Haemostasis, 1997, 78, 1183-8.	1.8	57
130	Protein S deficiency after varicella. Journal of Pediatrics, 1996, 129, 315.	0.9	6
131	P1. Diagnosis of APC resistance during pregnancy. Blood Coagulation and Fibrinolysis, 1996, 7, 388.	0.5	0
132	P25. Clinical reliability of the PT-derived fibrinogen assay. Blood Coagulation and Fibrinolysis, 1996, 7, 398.	0.5	0
133	Low thrombosis rate seen in blood donors and their relatives with inherited deficiencies of antithrombin and protein C. Blood Coagulation and Fibrinolysis, 1996, 7, 689-694.	0.5	24
134	Diagnosis of APC resistance during pregnancy. British Journal of Haematology, 1996, 92, 1026-1027.	1.2	20
135	Oral anticoagulation in paediatric patients: dose requirements and complications.. Archives of Disease in Childhood, 1996, 74, 228-231.	1.0	33
136	Noonan syndrome: coagulation and clinical aspects. Acta Paediatrica, International Journal of Paediatrics, 1996, 85, 1181-1185.	0.7	33
137	Diagnosis of APC resistance during pregnancy. British Journal of Haematology, 1996, 92, 1026-1027.	1.2	5
138	Isolated Familial Plasminogen Deficiency May not Be a Risk Factor for Thrombosis. Thrombosis and Haemostasis, 1996, 76, 1004-1008.	1.8	49
139	Hepatitis C virus infection in patients with lymphoproliferative disorders. British Journal of Haematology, 1996, 92, 771-3.	1.2	22
140	Isolated familial plasminogen deficiency may not be a risk factor for thrombosis. Thrombosis and Haemostasis, 1996, 76, 1004-8.	1.8	12
141	Two novel antithrombin variants, Asn187Asp and Asn187Lys, indicate a functional role for asparagine 187. Blood Coagulation and Fibrinolysis, 1995, 6, 51-54.	0.5	7
142	Development of resistance to activated protein C during pregnancy. British Journal of Haematology, 1995, 90, 725-727.	1.2	201
143	Flow cytometry in diagnosis and management of large fetomaternal haemorrhage.. Journal of Clinical Pathology, 1995, 48, 1005-1008.	1.0	46
144	Prevalence of Protein C Deficiency in the Healthy Population. Thrombosis and Haemostasis, 1995, 73, 087-093.	1.8	270

#	Article	IF	Citations
145	Prevalence of antithrombin deficiency in the healthy population. British Journal of Haematology, 1994, 87, 106-112.	1.2	346
146	Characteristics of Monoclonal Immunoglobulins That Interfere with Serum Inorganic Phosphate Measurement. Annals of Clinical Biochemistry, 1994, 31, 249-254.	0.8	27
147	Influence of demographic factors on antithrombin III activity in a healthy population. British Journal of Haematology, 1993, 84, 476-480.	1.2	56
148	Natural anticoagulants in smokers. American Heart Journal, 1993, 125, 1806.	1.2	0
149	Unilateral wheeze caused by pseudomembranous aspergillus tracheobronchitis in the immunocompromised patient.. Thorax, 1993, 48, 1285-1287.	2.7	24
150	Late spontaneous recovery of chronic thrombocytopenia.. Archives of Disease in Childhood, 1993, 68, 680-681.	1.0	17
151	Waldenstrom's macroglobulinaemia secreting a paraprotein with lupus anticoagulant activity: possible association with gastrointestinal tract disease and malabsorption.. Journal of Clinical Pathology, 1993, 46, 678-680.	1.0	13
152	Protein C activity in healthy volunteers--influence of age, sex, smoking and oral contraceptives. Thrombosis and Haemostasis, 1993, 70, 281-5.	1.8	6
153	Plasminogen levels in healthy volunteers--influence of age, sex, smoking and oral contraceptives. Thrombosis and Haemostasis, 1992, 68, 506-10.	1.8	6
154	Antithrombin Cambridge II, 384 Ala to Ser Further evidence of the role of the reactive centre loop in the inhibitory function of the serpins. FEBS Letters, 1991, 285, 248-250.	1.3	46
155	Subclinical pulmonary function defects following autologous and allogeneic bone marrow transplantation: Relationship to total body irradiation and graft-versus-host disease. International Journal of Radiation Oncology Biology Physics, 1991, 20, 1219-1227.	0.4	57
156	Age Related Changes in Protein C Activity in Healthy Adult Males. Thrombosis and Haemostasis, 1991, 65, 326-327.	1.8	13
157	Age related changes in protein C activity in healthy adult males. Thrombosis and Haemostasis, 1991, 65, 326-7.	1.8	0
158	ANTITHROMBIN III ACTIVITY IN HEALTHY BLOOD DONORS: AGE AND SEX RELATED CHANGES AND THE PREVALENCE OF ASYMPTOMATIC DEFICIENCY. British Journal of Haematology, 1990, 75, 141-142.	1.2	27
159	Toxoplasmosis after BMT for CML. Bone Marrow Transplantation, 1990, 5, 65-6.	1.3	5
160	Analysis of natural killer effector and suppressor activity by intraepithelial lymphocytes from mouse small intestine. Clinical and Experimental Immunology, 1983, 52, 191-8.	1.1	41